P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: COMPLETE INDUCTION PHASE ANALYSIS

• F. Lansigan,
• D. J. Andorsky,
• M. Coleman,
• A. Yacoub,
• J. M. Melear,
• S. R. Fanning,
• K. S. Kolibaba,
• C. Reynolds,
• G. S. Nowakowski,
• M. Gharibo,
• J. R. Ahn,
• J. Li,
• M. J. Rummel,
• J. P. Sharman

Affiliations

F. Lansigan

1 Dartmouth–Hitchcock Medical Center, Lebanon, NH

D. J. Andorsky

2 Rocky Mountain Cancer Centers, US Oncology Research, Boulder, CO

M. Coleman

3 Clinical Research Alliance Inc, Weill Cornell Medicine, New York, NY

A. Yacoub

4 University of Kansas Cancer Center, Westwood, KS

J. M. Melear

5 Texas Oncology — Austin, US Oncology Research, Austin, TX

S. R. Fanning

6 Prisma Health, US Oncology Research, Greenville, SC

K. S. Kolibaba

7 US Oncology Research, Vancouver, WA

C. Reynolds

8 IHA Hematology Oncology Consultants — Ann Arbor, Ypsilanti, MI

G. S. Nowakowski

9 Mayo Clinic, Rochester, MN

M. Gharibo

10 Bristol Myers Squibb, Princeton, NJ, United States of America

J. R. Ahn

10 Bristol Myers Squibb, Princeton, NJ, United States of America

J. Li

10 Bristol Myers Squibb, Princeton, NJ, United States of America

M. J. Rummel

11 Justus-Liebig-Universität, Giessen, Germany

J. P. Sharman

12 Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR, United States of America